Skip to main content

Developing and Sustaining Quality Management Systems in Compliance with Pharma Industry Standards: Corrective and Preventive Action (CAPA) Plans

RAPS Webinar

May
29
2019

Date: May 29, 2019

Time: 2:45PM - 4:00PM

Ben Zegarelli will speak on the topic, “Developing and Sustaining Quality Management Systems in Compliance with Pharma Industry Standards: Corrective and Preventive Action (CAPA) Plans" on a RAPS webinar.

Over the past few years there has been a growing expectation and increased standardization for Quality Management Systems (QMS) as it relates to clinical research in the pharma industry.  The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6 revision was just one example of a response to the need and demand for a more robust and documented system to ensure that procedures are established, and processes are in place to monitor compliance and analyze issues when they occur.

This program will address the growing requirements and expectations as it relates to root cause analysis, corrective and preventative action plans and implementation, aspects of a robust quality assurance program and how quality control can minimize errors and other quality issues. This program will support both the new and seasoned QMS manager or stakeholder to better understand the requirements, current industry trends for application and give them sample tools that can be used for quality management. 

Learning Objectives:

Upon conclusion of the program, you will be able to:

Identify and interpret regulatory requirements and industry standards as it relates to the development and maintenance of a QMS.
Provide input to a pharma organization regarding the rationale for a QMS including Quality Assurance and Quality Control programs.
Understand the basic elements of a root cause analysis (RCA) and corrective and preventative action (CAPA) plan.
Choose at least one tool for performing and documenting an RCA and / or CAPA.

Speakers

Benjamin advises pharmaceutical, medical device and biotech companies on the FDA regulatory process to identify the correct regulatory pathway, assisting with FDA communications and strategy.